What does Duality Biotherapeutics do?

Duality Biotherapeutics develops antibody-drug conjugates (ADCs). These are drugs that use an antibody to carry a potent payload directly to diseased cells, such as cancer cells. Its drug candidates are still in clinical trials and target cancers such as breast, endometrial, small-cell lung and prostate cancer, and the company is also working on autoimmune diseases.

Healthcare · Biotechnology · 9606.HK

What Duality Biotherapeutics Does & How It Makes Money (9606.HK)

Updated October 2026 · reflects Duality Biotherapeutics's latest reported financials

Clinical-stage Chinese biotech developing antibody-drug conjugates for cancer. The company has no approved products yet, so it depends on partnerships with larger drugmakers such as BioNTech, BeOne and Genentech to co-develop and commercialize its ADCs.

Duality Biotherapeutics's story, moat and numbers — in a 3-minute visual book.

Explore Duality Biotherapeutics on TacticScale →

How Duality Biotherapeutics makes money

The company has no approved products yet, so it depends on partnerships with larger drugmakers such as BioNTech, BeOne and Genentech to co-develop and commercialize its ADCs. Deals like these typically pay upfront and milestone fees, and future product sales could follow if its candidates are approved.

What Duality Biotherapeutics does

Duality Biotherapeutics is a Shanghai-based, clinical-stage biopharmaceutical company founded in 2019. It focuses on antibody-drug conjugates (ADCs) for cancer and autoimmune diseases. Its lead candidates are DB-1303/BNT323, a HER2-targeted ADC in development for endometrial and breast cancer, and DB-1311/BNT324, a B7-H3-targeted ADC being studied in small-cell lung cancer, castration-resistant prostate cancer, and esophageal and head and neck squamous cell carcinomas. Several other ADCs are also in clinical development. The company relies heavily on partnerships. It works with BioNTech on therapies meant to complement or replace chemotherapy, with BeOne on DB-1312, a B7-H4 ADC discovered in-house, and with Genentech on ADC development. Because none of its products are approved yet, its value rests on clinical trial results and on how these partnerships progress.

Products & services

DB-1303/BNT323 (HER2 ADC)
DB-1311/BNT324 (B7-H3 ADC)
DB-1312 (B7-H4 ADC, partnered with BeOne)
ADC discovery platform

What is Duality Biotherapeutics worth?

Fair value: not published

A reliable owner-earnings fair value isn't available for this company yet — we'd rather say so than print a number we don't trust.

We show a fair value only when the method is trustworthy. See Duality Biotherapeutics on TacticScale →

Sector Healthcare Industry Biotechnology HQ China Ticker 9606.HK Official site

Related companies

WuXi XDC Cayman (2268.HK) · Xencor (XNCR) · Bio-Thera Solutions (688177.SS) · Mabwell (Shanghai) Bioscience (688062.SS)

Understand Duality Biotherapeutics in 3 minutes →